Loading patent…
AssigneeSuntory Limited
InventorsYouichi Nunokawa, Shinzo Oikawa, Shoji Tanaka
Estimating the term…
A plasmid was constructed, in which the hiNOS structural gene was replaced with the luciferase structural gene as a reporter gene, with retaining functions of the hiNOS gene 5′-promoter region and 3′-untranslated region. This plasmid was stably transfected into human cell lines. The above transformed cells selectively expressed the reporter gene in the presence of inducers. It has become possible, by examining the reporter gene expression in these transformed cells, to simply and easily screen, with high sensitivity, a compound which is expected to be useful for treating inflammations and sepsis by suppressing the hiNOS expression, or a compound which is expected to be useful for antitumor, antiviral, and vascular restenosis prevention treatments by the hiNOS induction.
A DNA comprising a 3′-flanking region of the human inducible nitric oxide synthase (hiNOS) gene, wherein said 3′-flanking region confers inducible expression on an upstream coding sequence.
An expression vector comprising, in order, from the 5′ side:
A method of screening a substance which induces or suppresses human inducible nitric oxide synthase (hiNOS) gene expression, comprising:
A kit for screening a substance which induces or suppresses hiNOS gene expression, comprising a cell transformed with an expression vector comprising a reporter gene, a 3′-flanking region of the hiNOS gene and a 3′-UTR of the hiNOS gene;
A method for screening a substance which alters the activity of a specific substance that suppresses or induces hiNOS gene expression, comprising:
A kit for screening a substance which alters the activity of a specific substance that suppresses or induces hiNOS gene expression, comprising a cell transformed with an expression vector comprising a reporter gene, a 3′-flanking region of the hiNOS gene and a 3′-UTR of the hiNOS gene;
Dependencies are inferred from the claim text.